Quanterix Corp QTRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
-
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
-
Quanterix Names Jim Gute Chief Commercial Officer
-
Quanterix Releases Financial Results for the Second Quarter of 2026
-
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
-
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
-
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $3.41
- Day Range
- $3.44–3.69
- 52-Week Range
- $2.15–8.77
- Bid/Ask
- $3.39 / $3.70
- Shares Outstanding
- 47.29M
- Market Cap
- $172.15M
- Volume/Avg
- 590,808 / 745,913
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.05
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 450
- Website
- https://www.quanterix.com
Valuation
|
Metric
|
QTRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | 1.05 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
QTRX
|
|---|---|
Quick Ratio | 2.30 |
Current Ratio | 3.40 |
Interest Coverage | — |
Quick Ratio
QTRX
Profitability
|
Metric
|
QTRX
|
|---|---|
Return on Assets (Normalized) | −7.64% |
Return on Equity (Normalized) | −10.34% |
Return on Invested Capital (Normalized) | −10.47% |
Return on Assets
QTRX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Z#%$<# | LOCK|KWrbJ | $169B | |||
| Medtronic PLC
MDT
| LOCK|vGt!@Yv | LOCK|gX^p@ | $110B | |||
| Stryker Corp
SYK
| LOCK|mC%thjX | LOCK|FKk | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|TxDJZbz | LOCK|CqH! | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|vqq&qvXW | LOCK|YM%> | $49B | |||
| DexCom Inc
DXCM
| LOCK|g!>?Q!n@ | LOCK|T?^?? | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|$&Y&&%@ | LOCK|bc# | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|?k | LOCK|x< | $23B | |||
| Steris PLC
STE
| LOCK|#zP<cr@ | LOCK|Sk^! | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|T&$&lZ@ | LOCK|&&D | $17B |
United States